Skip to main content
68°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Personalis, Inc. - Common Stock
(NQ:
PSNL
)
4.630
+0.030 (+0.65%)
Streaming Delayed Price
Updated: 11:50 AM EDT, Aug 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Personalis, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Personalis Reports Second Quarter 2025 Financial Results
August 05, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Second Quarter 2025 Financial Results
July 22, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
July 09, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
June 03, 2025
From
Personalis, Inc.
Via
Business Wire
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
June 02, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
May 22, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
May 14, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Reports First Quarter 2025 Financial Results
May 06, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
April 28, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce First Quarter 2025 Financial Results
April 22, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
April 22, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
From
Personalis, Inc.
Via
Business Wire
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
March 03, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
February 18, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 28, 2025
From
Personalis, Inc.
Via
Business Wire
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
January 13, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
January 07, 2025
From
Personalis, Inc.
Via
Business Wire
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
December 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
December 19, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis and Tempus Expand Collaboration to Biopharma
December 16, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at Upcoming Investor Conferences
November 20, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the Stifel 2024 Healthcare Conference
November 05, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Third Quarter 2024 Financial Results
October 23, 2024
From
Personalis, Inc.
Via
Business Wire
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
September 16, 2024
From
Personalis, Inc.
Via
Business Wire
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
August 23, 2024
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Personalis to Participate at Upcoming Investor Conferences
August 22, 2024
From
Personalis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
